XML 28 R19.htm IDEA: XBRL DOCUMENT v3.21.1
Restatement of Previously Issued Financial Statements (Tables)
4 Months Ended
Dec. 31, 2020
Prior Period Adjustment [Abstract]  
Summary of Impact of the Restatement on the Balance Sheets, Statements of Operations and Statements of Cash Flows

The impact of the restatement on the balance sheets, statements of operations and statements of cash flows for the Affected Period is presented below. The restatement had no impact on net cash flows from operating, investing or financing activities.

 

 

 

As of December 31, 2020

 

 

 

As Previously

Reported

 

 

Restatement

Adjustment

 

 

As Restated

 

Balance Sheet

 

 

 

 

 

 

 

 

 

 

 

 

Total assets

 

$

346,090,177

 

 

$

-

 

 

$

346,090,177

 

Liabilities and stockholders’ equity

 

 

 

 

 

 

 

 

 

 

 

 

Total current liabilities

 

$

190,137

 

 

$

-

 

 

$

190,137

 

Deferred underwriting commissions

 

 

12,075,000

 

 

 

-

 

 

 

12,075,000

 

Derivative warrant liabilities

 

 

-

 

 

 

43,409,000

 

 

 

43,409,000

 

Total liabilities

 

 

12,265,137

 

 

 

43,409,000

 

 

 

55,674,137

 

Class A common stock, $0.0001 par value; shares subject to

   possible redemption

 

 

328,825,030

 

 

 

(43,409,000

)

 

 

285,416,030

 

Stockholders’ equity

 

 

 

 

 

 

 

 

 

 

 

 

Preferred stock- $0.0001 par value

 

 

-

 

 

 

-

 

 

 

-

 

Class A common stock - $0.0001 par value

 

 

162

 

 

 

434

 

 

 

596

 

Class B common stock - $0.0001 par value

 

 

863

 

 

 

-

 

 

 

863

 

Additional paid-in-capital

 

 

5,243,708

 

 

 

17,182,506

 

 

 

22,426,214

 

Accumulated deficit

 

 

(244,723

)

 

 

(17,182,940

)

 

 

(17,427,663

)

Total stockholders’ equity

 

 

5,000,010

 

 

 

-

 

 

 

5,000,010

 

Total liabilities and stockholders’ equity

 

$

346,090,177

 

 

$

-

 

 

$

346,090,177

 

 

 

 

Period From September 1, 2020 (Inception)

Through December 31, 2020

 

 

 

As Previously

Reported

 

 

Restatement

Adjustment

 

 

As Restated

 

Statement of Operations

 

 

 

 

 

 

 

 

 

 

 

 

Loss from operations

 

$

(248,295

)

 

$

(593,330

)

 

$

(841,625

)

Other (expense) income:

 

 

 

 

 

 

 

 

 

 

 

 

Change in fair value of derivative warrant liabilities

 

 

-

 

 

 

(15,515,670

)

 

 

(15,515,670

)

Financing costs - derivative warrant liabilities

 

 

-

 

 

 

(1,073,940

)

 

 

(1,073,940

)

Income from investments held in Trust Account

 

 

3,572

 

 

 

-

 

 

 

3,572

 

Total other (expense) income

 

 

3,572

 

 

 

(16,589,610

)

 

 

(16,586,038

)

Net loss

 

$

(244,723

)

 

$

(17,182,940

)

 

$

(17,427,663

)

Basic and Diluted weighted-average Class A common stock

   outstanding

 

 

32,910,507

 

 

 

(2,813,576

)

 

 

30,096,931

 

Basic and Diluted net loss per Class A common shares

 

$

-

 

 

 

 

 

 

$

-

 

Basic and Diluted weighted-average Class B common stock

   outstanding

 

 

8,959,895

 

 

 

1,513,184

 

 

 

10,473,079

 

Basic and Diluted net loss per Class B common shares

 

$

(0.03

)

 

$

(1.63

)

 

$

(1.66

)

 

 

 

Period From September 1, 2020 (Inception)

Through December 31, 2020

 

 

 

As Previously

Reported

 

 

Restatement

Adjustment

 

 

As Restated

 

Statement of Cash Flows

 

 

 

 

 

 

 

 

 

 

 

 

Net loss

 

$

(244,723

)

 

$

(17,182,940

)

 

$

(17,427,663

)

Adjustments to reconcile net loss to net cash used in operating

   activities

 

 

(3,572

)

 

 

17,182,940

 

 

 

17,179,368

 

Net cash used in operating activities

 

 

(579,288

)

 

 

-

 

 

 

(579,288

)

Net cash used in investing activities

 

 

(345,000,000

)

 

 

-

 

 

 

(345,000,000

)

Net cash provided by financing activities

 

 

346,217,113

 

 

 

-

 

 

 

346,217,113

 

Net change in cash

 

$

637,825

 

 

$

-

 

 

$

637,825